Asymchem Laboratories (Tianjin) Co., Ltd. and AUM Biosciences Pte. Ltd. announced a collaboration agreement. Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
68.2 CNY | +4.04% |
|
+10.70% | -41.26% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.26% | 3.09B | |
+55.35% | 848B | |
+31.64% | 627B | |
-0.10% | 363B | |
+15.47% | 318B | |
+13.10% | 299B | |
+15.51% | 243B | |
+16.72% | 225B | |
+16.54% | 179B | |
+4.31% | 167B |
- Stock Market
- Equities
- 002821 Stock
- News Asymchem Laboratories (Tianjin) Co., Ltd.
- AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor